Trevi Therapeutics Inc. (TRVI) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±11.2% realized swing band)
FRED Regime × Technicals: 38% of 52W Range • RSI-14 at 50.7 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While TRVI currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.69) and Max Pain ($14.50) forces dealer call-delta covering toward $21.23.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Trevi Therapeutics Inc. (TRVI) surged +2.15% to $13.81, trading at 38% of its 52-week range ($9.82 – $20.22). Stretched risk/reward at current multiples (-24% return on capital) under elevated 10-year interest-rate pressure.
Fireside chat with management on Wednesday, November 11, 2026, at 10:00 a.m. ETNEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company devel
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TRVI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TRVI. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Trevi Therapeutics Inc. (TRVI) ranks #661 by composite RQD confidence (39/100, grade D-) and #266 by equity capitalization ($1.97B). Within this direct 5-issuer industry benchmark cohort, TRVI leads on earnings valuation at N/A trailing P/E, while XERS leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. XERS currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with TRVI at 39/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TRVI
ACTIVE
Trevi Therapeutics Inc. | D- | 39/100 | — | — | -23.7% | +2.15% | $1.97B | Benchmark Subject |
| XERS Xeris Biopharma Holdings Inc. | C | 62/100 | — | — | 16.0% | +1.03% | $1.96B | /xers-vs-trvi → |
| ZYME Zymeworks Inc. | D | 47/100 | — | — | -32.2% | -0.66% | $2.02B | /zyme-vs-trvi → |
| GENB Generate Biomedicines Inc. | C- | 61/100 | — | — | — | +2.54% | $2.02B | /genb-vs-trvi → |
| BRVE Braveheart Bio Inc. | D | 47/100 | — | — | — | -2.62% | $1.91B | /brve-vs-trvi → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Trevi Therapeutics Inc. (TRVI) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$42.8M, operating cash flow of -$42.1M, and free cash flow of -$42.1M (-10.0% YoY). On the balance sheet, TRVI closed FY2025 with $193.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$42.8M | -$42.1M | -$42.1M | $193.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$47.9M | -$38.3M | -$38.3M | $110.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$29.1M | -$31.7M | -$31.7M | — | — |
As of 2026-11-01, Trevi Therapeutics Inc. (NASDAQ: TRVI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $13.81 (+2.15% 1D, market cap $1.97B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TRVI ranks #661 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TRVI carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -23.7%. By comparison, XERS (Xeris Biopharma Holdings Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC 16.0%, cap $1.96B) and ZYME (Zymeworks Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -32.2%, cap $2.02B). Among the 5-stock peer group, TRVI leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).
Per TRVI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001563880), Trevi Therapeutics Inc. generated $0 in revenue, -$42.8M in net income, and -$42.1M in free cash flow against $193.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
TRVI last traded at $13.81 (+2.15% on volume of 1,345,331 shares), positioning the stock -5.99% below its 50-day simple moving average ($14.69) and -3.70% below its 200-day simple moving average ($14.34). Across its 52-week range of $9.82 to $20.22, TRVI sits at the 38.4% percentile with a 14-day RSI of 50.7 (NEUTRAL RANGE) and an implied next-earnings move of ±11.2% ($12.26 to $15.36).
Why TRVI Stock surged +2.15% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-24% return on capital) under elevated 10-year interest-rate pressure.